期刊文献+

Luminal-B型乳腺癌,你的靶点在哪里?

Luminal-B breast cancer, where is your target?
在线阅读 下载PDF
导出
摘要 基因表达图谱将乳腺癌分为4种亚型:基底亚型、HER2阳性亚型、luminal-A亚型和luminal-B亚型。尽管都表达雌激素受体,也都接受了内分泌治疗,但luminal-B亚型较luminal-A亚型的复发风险明显增加。Luminal-B亚型的典型特点是高表达增殖相关基因,一些可能改善其预后的相关信号通路靶点也在研究中。本文回顾了luminal-B亚型乳腺癌的基因表达特点、病理和临床特征以及目前正在研发的治疗靶点。 Breast cancer can be classified into four intrinsic subtypes by gene expression profiling: basal-like, HER2- positive, luminal-A and luminal-B. In spite of expressing estrogen receptor, the luminal-B subtype runs an increased risk for early relapse compared with the luminal-A subtype, even if receiving endocrine therapy. Luminal-B subtype is typically identified by high expressions of proliferation-related genes. Some novel signaling pathways are being studied to improve survival. This article reviewed the gene expression characteristics, pathological and clinical features of luminal-B breast cancer, and potential targets for treatment.
出处 《医学争鸣》 CAS 北大核心 2014年第2期10-13,共4页 Negative
基金 第四军医大学西京医院学科助推计划(XJZT10Y24)
关键词 乳腺癌 LUMINAL B亚型 靶点 breast cancer luminal B subtype target
  • 相关文献

参考文献20

  • 1Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797):747-752.
  • 2Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer[J]. N Engl J Med, 2009, 360(8):790-800.
  • 3Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms[J]. BMC Genomics, 2006, 27(7):96.
  • 4Ignatiadis M, Bedard P, Haibe-Kains B, et al. A meta-analysis of gene expression profiling studies identifies clinically relevant oncogenic pathways in basal like breast cancer[J]. Cancer Res, 2009, 69(24):S106.
  • 5Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse[J]. Cancer Res, 2008, 68(9): 3108-3114.
  • 6Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor- positive breast cancer[J]. J Clin Oncol, 2006, 24(23):3726-3734.
  • 7Bhargava R, Beriwal S, Dabbs D J, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases[J]. Cancer, 2010, 116(6):1431-1439.
  • 8Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer[J]. J Natl Cancer Inst, 2007, 99(2):167-170.
  • 9Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer[J]. J Natl Cancer Inst, 2009, 101(10):736-750.
  • 10Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer[J]. J Clin Oncol, 2007,25(33):5287-5312.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部